bioRxivImmunologyPreprint
TGFβ Suppresses Type 2 Immunity to Cancer
M. Liu, F. Kuo, K. Capistrano, D. Kang, B. Nixon, W. Shi, C. Chou, M. Do, S. Li, E. Stamatiades, Y. Chen, J. Hsieh, A. Hakimi, I. Taniuchi, T. Chan, M. Li
Abstract
The immune system employs two distinct defense strategies against infections: pathogen elimination typified by type 1 immunity, and pathogen containment exemplified by type 2 immunity in association with tissue repair. Akin to infectious diseases, cancer progresses with cancer cell acquisition of microorganism-like behavior propagating at the expense of the host. While immunological mechanisms of cancer cell elimination are well defined, whether immune-mediated cancer cell containment can be induced is poorly understood. Here we show that ablation of transforming growth factor-{beta} receptor II (TGF{beta}RII) in CD4+ T cells promotes tumor tissue healing and halts cancer progression. Notably, the restorative response is dependent on the T helper 2 cytokine IL-4 fortifying vasculature organization that spares only proximal layers of cancer cells from hypoxia, nutrient starvation and death. Thus, type 2 immunity represents an effective cancer defense mechanism, and TGF{beta} signaling in helper T cells may be targeted for novel cancer immunotherapy.
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TLR2 signaling uniquely destabilizes tumor Tregs to promote cancer immunotherapy
Timothy F. Campbell, Jesse Garcia Castillo, … Michel J.P. DuPage·bioRxiv·Jun 26, 2025
- CD4+ T-Cells Drive Triple Negative Breast Cancer Recurrence via Non-Canonical TGFβ Signaling
McKenzie A. Mayeaux, Benjamin P. Altman, … Marjan Rafat·bioRxiv·Aug 20, 2026
- Cancer cell CCR2 orchestrates suppression of the adaptive immune response
M. R. Fein, X. Y. He, … M. Egeblad·bioRxiv·Dec 27, 2019
- The central THαβ immunity associated cytokine: IL-10 has a strong anti-tumor ability toward established cancer models in vivo and toward cancer cells in vitro
W. Hu·bioRxiv·Oct 19, 2020
- TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy
P. Hamon, M. Gerbe de Thore, … M. Mondini·bioRxiv·Jan 17, 2022
- A dramatic impairment of the antitumor activity of human Vgamma9Vdelta2 T cells is induced by TGF-beta through significant phenotype, transcriptomic and metabolic changes
C. RAFIA, C. LOIZEAU, … E. SCOTET·bioRxiv·Sep 22, 2022